<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">zdor</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы здоровья и экологии</journal-title><trans-title-group xml:lang="en"><trans-title>Health and Ecology Issues</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2220-0967</issn><issn pub-type="epub">2708-6011</issn><publisher><publisher-name>Gomel State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51523/2708-6011.2025-22-3-02</article-id><article-id custom-type="elpub" pub-id-type="custom">zdor-2851</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКАЯ МЕДИЦИНА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINICAL MEDICINE</subject></subj-group></article-categories><title-group><article-title>Остеопротегерин как диагностический показатель хронической ишемии нижних конечностей вследствие облитерирующего атеросклероза, сочетающегося с сахарным диабетом 2 типа, и фактор прогноза при ее хирургическом лечении</article-title><trans-title-group xml:lang="en"><trans-title>Osteoprotegerin as a diagnostic indicator of chronic lower limb ischemia due to obliterating atherosclerosis combined with type 2 diabetes mellitus, and prognostic factor in its surgical treatment</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5842-0209</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Обухович</surname><given-names>А. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Obuhovich</surname><given-names>A. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Обухович Аннета Ромуальдовна - ассистент 1-й кафедры хирургических болезней, соискатель 1-й кафедры хирургических болезней.</p><p>Гродно</p></bio><bio xml:lang="en"><p>Anneta R. Obuhovich - Assistant at the 1st Department of Surgical Diseases, Applicant at the 1st Department of Surgical Diseases.</p><p>Grodno</p></bio><email xlink:type="simple">anneta.panasiuk@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2954-0452</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Иоскевич</surname><given-names>Н. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Iaskevich</surname><given-names>N. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Иоскевич Николай Николаевич - д.м.н., профессор, заведующий 1-й кафедрой хирургических болезней.</p><p>Гродно</p></bio><bio xml:lang="en"><p>Nikolai N. Iaskevich - Doctor of Medical Sciences, Professor, Head of the 1st Department of Surgical Diseases.</p><p>Grodno</p></bio><email xlink:type="simple">inngrno@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9509-8909</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шулика</surname><given-names>В. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Shulika</surname><given-names>V. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шулика Валентина Ришардовна - сотрудник отраслевой лаборатории молекулярной медицины.</p><p>Гродно</p></bio><bio xml:lang="en"><p>Valentina R. Shulika - Staff Member at the Branch Laboratory of Molecular Medicine.</p><p>Grodno</p></bio><email xlink:type="simple">valentina_sh67@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5513-970X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бабенко</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Babenka</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бабенко Андрей Сергеевич - биолог клинико-диагностической лаборатории.</p><p>Минск</p></bio><bio xml:lang="en"><p>Andrei S. Babenka - Biologist at the Clinical Diagnostic Laboratory.</p><p>Minsk</p></bio><email xlink:type="simple">labmdbt@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-6607-5459</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ждонец</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Zhdonets</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ждонец Светлана Вячеславовна - заведующий отделением гнойной хирургии.</p><p>Гродно</p></bio><bio xml:lang="en"><p>Svetlana V. Zhdonets - Head of the Purulent Surgery Department.</p><p>Grodno</p></bio><email xlink:type="simple">trushsvetlanka37@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Гродненский государственный медицинский университет</institution></aff><aff xml:lang="en"><institution>Grodno State Medical University</institution></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Республиканский научно-практический центр «Кардиология»</institution></aff><aff xml:lang="en"><institution>Republican Scientific and Practical Center “Cardiology”</institution></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Гродненская университетская клиника</institution></aff><aff xml:lang="en"><institution>Grodno University Clinic</institution></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>27</day><month>09</month><year>2025</year></pub-date><volume>22</volume><issue>3</issue><fpage>15</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Обухович А.Р., Иоскевич Н.Н., Шулика В.Р., Бабенко А.С., Ждонец С.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Обухович А.Р., Иоскевич Н.Н., Шулика В.Р., Бабенко А.С., Ждонец С.В.</copyright-holder><copyright-holder xml:lang="en">Obuhovich A.R., Iaskevich N.N., Shulika V.R., Babenka A.S., Zhdonets S.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.gsmu.by/jour/article/view/2851">https://journal.gsmu.by/jour/article/view/2851</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Определить концентрацию остеопротегерина (ОПГ) в плазме венозной крови при хронической ишемии нижних конечностей вследствие облитерирующего атеросклероза (ОА), сочетающегося с сахарным диабетом (СД) 2 типа, и влияние его динамики на прогрессирование заболевания после открытых и рентгенэндоваскулярных операций.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Концентрация ОПГ в плазме венозной крови изучалась у 221 пациента с хронической ишемией нижних конечностей атеросклеротического генеза. Были сформированы две группы: группа 1 (n = 92) — пациенты с ОА без нарушения углеводного обмена, группа 2 (n = 129) — пациенты с ОА с сопутствующим СД 2 типа. Группы сравнения составили пациенты с СД 2 типа без признаков ОА (группа 3, n = 16) и условно здоровые пациенты (группа 4, n = 51). В группе 2 наблюдались 24 месяца после выполнения реваскуляризирующей операции 78 пациентов. В зависимости от исхода операции пациенты были разделены на группы 2А (с сохраненной нижней конечностью, n = 60; 76,92 %) и 2Б (с ампутированной нижней конечностью, n = 18; 23,08 %).</p></sec><sec><title>Результаты</title><p>Результаты. Сочетание ОА нижних конечностей и СД 2 типа характеризуется повышением концентрации ОПГ в плазме по сравнению с аналогичным показателем у здоровых лиц, пациентов с изолированным атеросклерозом артерий нижних конечностей, а также с изолированным СД 2 типа (р &lt; 0,001). Пороговым значением уровня ОПГ, превышение которого свидетельствует о высокой вероятности наличия ОА, у пациентов с СД 2 типа является 189,37 пг/мл. Исходные показатели ОПГ у пациентов группы 2А (с сохраненной нижней конечностью после артериальной реваскуляризации) и группы 2Б (с ампутированной нижней конечностью после артериальной реваскуляризации) были сопоставимы между собой. Однако у пациентов группы 2А концентрация ОПГ постепенно достоверно снижалась через 14 дней и через 3 месяца, в то время как у пациентов группы 2Б этот показатель увеличивался, предшествуя ампутации нижней конечности в вышеуказанные сроки.</p></sec><sec><title>Заключение</title><p>Заключение. Остеопротегерин плазмы венозной крови может рассматриваться как один из диагностических факторов наличия ОА у пациентов с СД 2 типа. Изучение его динамики в послеоперационном периоде целесообразно использовать для проведения комплекса лечебных мероприятий по предупреждению неблагоприятного исхода артериальной реваскуляризации.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To determine the concentration of osteoprotegerin in venous blood plasma in chronic lower limb ischemia due to obliterating atherosclerosis combined with type 2 diabetes mellitus, and the effect of its dynamics on the disease progression after open and roentgen-endovascular surgeries.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. Concentration of osteoprotegerin in venous blood plasma was studied in 221 patients with chronic lower limb ischemia of atherosclerotic genesis. Two groups were formed: Group 1 (n=92) – patients with obliterating atherosclerosis without carbohydrate metabolism disorders, Group 2 (n=129) – patients with obliterating atherosclerosis and concomitant type 2 diabetes mellitus. The comparison groups included patients with type 2 diabetes mellitus without signs of obliterating atherosclerosis (Group 3, n=16), and conditionally healthy patients (Group 4, n=51). 78 patients were followed for 24 months after revascularization surgery in Group 2. The patients were divided into Group 2A (with preserved lower limb, n=60; 76.92%) and Group 2B (with amputated lower limb, n=18; 23.08%) depending on the outcome of the operation.</p></sec><sec><title>Results</title><p>Results. The combination of obliterating atherosclerosis of the lower limbs and type 2 diabetes mellitus is characterized by an increase in the concentration of osteoprotegerin in plasma compared to healthy individuals, patients with isolated atherosclerosis of the arteries of the lower limbs, as well as isolated type 2 diabetes mellitus (p&lt;0.001). The threshold value of the osteoprotegerin level, the excess of which indicates a high probability of the presence of obliterating atherosclerosis in patients with type 2 diabetes mellitus is 189.37 pg/ml. The initial osteoprotegerin values in patients of Group 2A (with preserved lower limb after arterial revascularization) and Group 2B (with amputated lower limb) limb after arterial revascularization) were comparable. However, in patients of Group 2A, the concentration of osteoprotegerin gradually decreased significantly after 14 days and 3 months, while in patients of group 2B this indicator increased, preceding the amputation of the lower limb in the above-mentioned periods.</p></sec><sec><title>Conclusion</title><p>Conclusion. Osteoprotegerin of venous blood plasma can be considered as one of the diagnostic factors for the presence of obliterating atherosclerosis in patients with type 2 diabetes mellitus. It is advisable to study its dynamics in the postoperative period for carrying out a set of therapeutic measures to prevent an unfavorable outcome of arterial revascularization.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>облитерирующий атеросклероз</kwd><kwd>сахарный диабет 2 типа</kwd><kwd>остеопротегерин</kwd><kwd>костный метаболизм</kwd><kwd>артериальная реваскуляризация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>obliterating atherosclerosis</kwd><kwd>type 2 diabetes mellitus</kwd><kwd>osteoprotegerin</kwd><kwd>bone metabolism</kwd><kwd>arterial revascularization</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнялась в рамках гранта БРФФИ «Наука М-23», № М23М-098 от 02.05.2023 г. (№ гос. регистрации 20231274), по теме: «Роль остеопротегерина, эндотелина-1 и полиморфизма их генов в развитии хронической критической ишемии нижних конечностей при облитерирующем атеросклерозе, сочетающемся с сахарным диабетом, и исходах артериальных реконструкций». Финансовой поддержки со стороны компаний-производителей лекарственных препаратов авторы не получали</funding-statement><funding-statement xml:lang="en">The work was carried out within the grant of Belarusian Republican Foundation for Fundamental Reserch “Science M-23” No. M23M-098 dated 02.05.2023 (State Registration No. 20231274) on the topic: “The role of osteoprotegerin, endothelin-1 and polymorphism of their genes in the development of chronic critical ischemia of the lower extremities in obliterating atherosclerosis combined with diabetes mellitus, and the outcomes of arterial reconstructions”. The authors did not receive financial support from drug manufacturers</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">10 ведущих причин смерти в мире [Электронный ресурс]. Глобальный веб-сайт Всемирной организации здравоохранения. [дата обращения 2024 Август 7]. Режим доступа: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death</mixed-citation><mixed-citation xml:lang="en">The top 10 causes of death [Electronic resource]. Global website of the world health organization. [data of access 2024 August 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Диабет [Электронный ресурс]. Глобальный веб-сайт Всемирной организации здравоохранения. [дата обращения 2024 Ноябрь 14]. Режим доступа: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes</mixed-citation><mixed-citation xml:lang="en">Diabetes [Electronic resource]. Global website of the world health organization. [data of access 2024 November 7]. Available from: https://www.who.int/ru/news-room/fact-sheets/detail/diabetes (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ткаченко А.Н., Бахтин М.Ю., Жарков А.В., Антонов Д.В., Хачатрян Е.С., Сидоренко В.А. Прогноз летальных исходов при проведении ампутаций нижней конечности у больных пожилого и старческого возраста. Фундаментальные исследования. 2011;9(2):304-308.</mixed-citation><mixed-citation xml:lang="en">Tkachenko AN, Bakhtin MJu, Zharkov AV, Antonov DV, Khachatryan ES, Sidorenko VA. Forecast of death in the conduct of amputation of the lower extremities in patients elderly and senile age. Fundamental research. 2011;9-2:304-308. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Обухович А.Р., Иоскевич Н.Н. Патофизиологическая роль остеопротегерина при атеросклерозе и сахарном диабете. Журнал Гродненского государственного медицинского университета. 2022;20(2):129-136. DOI: https://doi.org/10.25298/2221-8785-2022-20-2-129-136</mixed-citation><mixed-citation xml:lang="en">Obuhovich AR, Iaskevich NN. Оsteoprotegerin as a marker of atherosclerosis in type 2 diabetes mellitus (pathophysiological role of оsteoprotegerin). Journal of the Grodno State Medical University. 2022;20(2):129-136. (In Russ.). DOI: https://doi.org/10.25298/2221-8785-2022-20-2-129-136</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Demer LL. Cholesterol in vascular and valvular calcification. Circulation. 2001;104(16):1881-1883. DOI: https://doi.org/10.1161/circ.104.16.1881</mixed-citation><mixed-citation xml:lang="en">Demer LL. Cholesterol in vascular and valvular calcification. Circulation. 2001;104(16):1881-1883. DOI: https://doi.org/10.1161/circ.104.16.1881</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Demkova K, Kozarova M, Malachovska Z, Javorsky M, Tkac I. Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus. Vasa. 2018;147(2):131–135. DOI: https://doi.org/10.1024/0301-1526/a000682</mixed-citation><mixed-citation xml:lang="en">Demkova K, Kozarova M, Malachovska Z, Javorsky M, Tkac I. Osteoprotegerin concentration is associated with the presence and severity of peripheral arterial disease in type 2 diabetes mellitus. Vasa. 2018;147(2):131–135. DOI: https://doi.org/10.1024/0301-1526/a000682</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Shui X, Dong R, Wu Z, Chen Z, Wen Z, Tang L, et al. Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction. BMC Cardiovascular Disorders. 2022;22(1):213. DOI: https://doi.org/10.1186/s12872-022-02654-1</mixed-citation><mixed-citation xml:lang="en">Shui X, Dong R, Wu Z, Chen Z, Wen Z, Tang L, et al. Association of serum sclerostin and osteoprotegerin levels with the presence, severity and prognosis in patients with acute myocardial infarction. BMC Cardiovascular Disorders. 2022;22(1):213. DOI: https://doi.org/10.1186/s12872-022-02654-1</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Andersen GO, Knudsen EC, Aukrust P, Yndestad A, Oie E, Muller C, et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart. 2011;97(6):460-465. DOI: https://doi.org/10.1136/hrt.2010.206714</mixed-citation><mixed-citation xml:lang="en">Andersen GO, Knudsen EC, Aukrust P, Yndestad A, Oie E, Muller C, et al. Elevated serum osteoprotegerin levels measured early after acute ST-elevation myocardial infarction predict final infarct size. Heart. 2011;97(6):460-465. DOI: https://doi.org/10.1136/hrt.2010.206714</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Cappareli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-1268. DOI: https://doi.org/10.1101/gad.12.9.1260</mixed-citation><mixed-citation xml:lang="en">Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Cappareli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12(9):1260-1268. DOI: https://doi.org/10.1101/gad.12.9.1260</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, et al. The potential role of the osteopontin–osteocalcin–osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetologica. 2018;55(2):139-148. DOI: https://doi.org/10.1007/s00592-017-1065-Z</mixed-citation><mixed-citation xml:lang="en">Daniele G, Winnier D, Mari A, Bruder J, Fourcaudot M, Pengou Z, et al. The potential role of the osteopontin–osteocalcin–osteoprotegerin triad in the pathogenesis of prediabetes in humans. Acta Diabetologica. 2018;55(2):139-148. DOI: https://doi.org/10.1007/s00592-017-1065-Z</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Nardella E, Biscetti F, Rando MM, Cecchini AL, Nicolazzi MA, Rossini E, et al. Development of a biomarker panel for assessing cardiovascular risk in diabetic patients with chronic limb-threatening ischemia (CLTI): a prospective study. Cardiovascular Diabetology. 2023;22(1):136. DOI: https://doi.org/10.1186/s12933-023-01872-x</mixed-citation><mixed-citation xml:lang="en">Nardella E, Biscetti F, Rando MM, Cecchini AL, Nicolazzi MA, Rossini E, et al. Development of a biomarker panel for assessing cardiovascular risk in diabetic patients with chronic limb-threatening ischemia (CLTI): a prospective study. Cardiovascular Diabetology. 2023;22(1):136. DOI: https://doi.org/10.1186/s12933-023-01872-x</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Barbarash O, Zykov M, Kashtalap V, Hryachkova O, Kokov A, Gruzdeva O, et al. Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery. Diagnostics. 2019;9(4):143. DOI: https://doi.org/10.3390/diagnostics9040143</mixed-citation><mixed-citation xml:lang="en">Barbarash O, Zykov M, Kashtalap V, Hryachkova O, Kokov A, Gruzdeva O, et al. Increased Serum Parathyroid Hormone, Osteocalcin and Alkaline Phosphatase Are Associated with a Long-Term Adverse Cardiovascular Outcome after Coronary Artery Bypass Graft Surgery. Diagnostics. 2019;9(4):143. DOI: https://doi.org/10.3390/diagnostics9040143</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Hermann-Arnhof KM, Kastenbauer T, Publig T, Novotny P, Loho N, Schwarz S, et al. Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. Critical care medicine. 2006;34(1):76-80. DOI: https://doi.org/10.1097/01.ccm.0000190429.52746.33</mixed-citation><mixed-citation xml:lang="en">Hermann-Arnhof KM, Kastenbauer T, Publig T, Novotny P, Loho N, Schwarz S, et al. Initially elevated osteoprotegerin serum levels may predict a perioperative myocardial lesion in patients undergoing coronary artery bypass grafting. Critical care medicine. 2006;34(1):76-80. DOI: https://doi.org/10.1097/01.ccm.0000190429.52746.33</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Giovannini S, Tinelli G, Biscetti F, Straface G, Angelini F, Pitocco D, et al. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovascular Diabetology. 2017;16(1):99. DOI: https://doi.org/10.1186/s12933-017-0581-z</mixed-citation><mixed-citation xml:lang="en">Giovannini S, Tinelli G, Biscetti F, Straface G, Angelini F, Pitocco D, et al. Serum high mobility group box-1 and osteoprotegerin levels are associated with peripheral arterial disease and critical limb ischemia in type 2 diabetic subjects. Cardiovascular Diabetology. 2017;16(1):99. DOI: https://doi.org/10.1186/s12933-017-0581-z</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
